vs
Side-by-side financial comparison of Armour Residential REIT, Inc. (ARR) and Phathom Pharmaceuticals, Inc. (PHAT). Click either name above to swap in a different company.
Phathom Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($57.6M vs $50.4M, roughly 1.1× Armour Residential REIT, Inc.). On growth, Armour Residential REIT, Inc. posted the faster year-over-year revenue change (297.9% vs 94.1%).
Armour Residential REIT, Inc. is a U.S.-based real estate investment trust that primarily invests in agency residential mortgage-backed securities guaranteed by U.S. government-sponsored entities. It focuses on generating consistent long-term net income for shareholders via strategic asset management and active interest rate risk mitigation.
Phathom Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative therapies for gastrointestinal diseases. Its lead product candidates address acid-related disorders, inflammatory bowel disease, and other GI conditions, serving patients mainly across North America and Europe.
ARR vs PHAT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $50.4M | $57.6M |
| Net Profit | $211.7M | — |
| Gross Margin | — | 86.7% |
| Operating Margin | — | — |
| Net Margin | 420.2% | — |
| Revenue YoY | 297.9% | 94.1% |
| Net Profit YoY | 555.9% | 71.6% |
| EPS (diluted) | $2.43 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $50.4M | $57.6M | ||
| Q3 25 | $38.5M | $49.5M | ||
| Q2 25 | $33.1M | $39.5M | ||
| Q1 25 | $36.3M | $28.5M | ||
| Q4 24 | $12.7M | $29.7M | ||
| Q3 24 | — | $16.4M | ||
| Q2 24 | $7.0M | $7.3M | ||
| Q1 23 | $12.2M | — |
| Q4 25 | $211.7M | — | ||
| Q3 25 | $159.3M | $-30.0M | ||
| Q2 25 | $-75.6M | $-75.8M | ||
| Q1 25 | $27.3M | $-94.3M | ||
| Q4 24 | $-46.4M | — | ||
| Q3 24 | — | $-85.6M | ||
| Q2 24 | $-48.4M | $-91.4M | ||
| Q1 23 | $-31.4M | — |
| Q4 25 | — | 86.7% | ||
| Q3 25 | — | 87.5% | ||
| Q2 25 | — | 87.2% | ||
| Q1 25 | — | 86.9% | ||
| Q4 24 | — | 87.1% | ||
| Q3 24 | — | 85.6% | ||
| Q2 24 | — | 81.2% | ||
| Q1 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -30.8% | ||
| Q2 25 | — | -151.7% | ||
| Q1 25 | — | -276.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -433.0% | ||
| Q2 24 | — | -1055.4% | ||
| Q1 23 | — | — |
| Q4 25 | 420.2% | — | ||
| Q3 25 | 413.5% | -60.5% | ||
| Q2 25 | -228.4% | -191.9% | ||
| Q1 25 | 75.2% | -330.7% | ||
| Q4 24 | -366.8% | — | ||
| Q3 24 | — | -523.3% | ||
| Q2 24 | -693.8% | -1248.6% | ||
| Q1 23 | -256.8% | — |
| Q4 25 | $2.43 | — | ||
| Q3 25 | $1.49 | $-0.41 | ||
| Q2 25 | $-0.94 | $-1.05 | ||
| Q1 25 | $0.32 | $-1.31 | ||
| Q4 24 | $-0.91 | — | ||
| Q3 24 | — | $-1.32 | ||
| Q2 24 | $-1.05 | $-1.56 | ||
| Q1 23 | $-0.95 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.3M | $130.0M |
| Total DebtLower is stronger | — | $209.1M |
| Stockholders' EquityBook value | $2.3B | $-438.2M |
| Total Assets | $21.0B | $259.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.3M | $130.0M | ||
| Q3 25 | $44.2M | $135.2M | ||
| Q2 25 | $141.2M | $149.6M | ||
| Q1 25 | $49.1M | $212.3M | ||
| Q4 24 | $68.0M | $297.3M | ||
| Q3 24 | — | $334.7M | ||
| Q2 24 | $126.6M | $276.2M | ||
| Q1 23 | — | — |
| Q4 25 | — | $209.1M | ||
| Q3 25 | — | $207.1M | ||
| Q2 25 | — | $205.1M | ||
| Q1 25 | — | $203.2M | ||
| Q4 24 | — | $201.4M | ||
| Q3 24 | — | $175.7M | ||
| Q2 24 | — | $174.4M | ||
| Q1 23 | — | — |
| Q4 25 | $2.3B | $-438.2M | ||
| Q3 25 | $2.1B | $-422.5M | ||
| Q2 25 | $1.7B | $-405.8M | ||
| Q1 25 | $1.7B | $-338.4M | ||
| Q4 24 | $1.4B | $-253.6M | ||
| Q3 24 | — | $-187.1M | ||
| Q2 24 | $1.2B | $-233.8M | ||
| Q1 23 | $1.2B | — |
| Q4 25 | $21.0B | $259.1M | ||
| Q3 25 | $19.4B | $240.3M | ||
| Q2 25 | $16.2B | $250.2M | ||
| Q1 25 | $15.5B | $294.2M | ||
| Q4 24 | $13.5B | $378.3M | ||
| Q3 24 | — | $387.0M | ||
| Q2 24 | $10.1B | $319.4M | ||
| Q1 23 | $13.2B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $124.2M | $-166.8M |
| Free Cash FlowOCF − Capex | — | $-167.0M |
| FCF MarginFCF / Revenue | — | -290.0% |
| Capex IntensityCapex / Revenue | — | 0.4% |
| Cash ConversionOCF / Net Profit | 0.59× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-328.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $124.2M | $-166.8M | ||
| Q3 25 | $-37.8M | $-14.1M | ||
| Q2 25 | $25.0M | $-62.7M | ||
| Q1 25 | $101.5M | $-84.9M | ||
| Q4 24 | $261.5M | $-266.8M | ||
| Q3 24 | — | $-63.6M | ||
| Q2 24 | $27.1M | $-70.7M | ||
| Q1 23 | $54.2M | — |
| Q4 25 | — | $-167.0M | ||
| Q3 25 | — | $-14.1M | ||
| Q2 25 | — | $-62.8M | ||
| Q1 25 | — | $-84.9M | ||
| Q4 24 | — | $-266.9M | ||
| Q3 24 | — | $-63.6M | ||
| Q2 24 | — | $-70.8M | ||
| Q1 23 | — | — |
| Q4 25 | — | -290.0% | ||
| Q3 25 | — | -28.6% | ||
| Q2 25 | — | -159.0% | ||
| Q1 25 | — | -297.9% | ||
| Q4 24 | — | -899.8% | ||
| Q3 24 | — | -389.0% | ||
| Q2 24 | — | -966.2% | ||
| Q1 23 | — | — |
| Q4 25 | — | 0.4% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.6% | ||
| Q1 23 | — | — |
| Q4 25 | 0.59× | — | ||
| Q3 25 | -0.24× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.71× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
